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Obesity-related complications have emerged as increasing socioeconomic problems alongside the worldwide epidemic of obesity.[@bib1], [@bib2], [@bib3] The kidney is 1 of the target organs for obesity-related health disorders, and obesity is an independent risk factor for the development of kidney disease.[@bib4]^,^[@bib5] A well-characterized renal complication of obesity is obesity-related glomerulopathy (ORG).[@bib6], [@bib7], [@bib8], [@bib9], [@bib10] Since the first autopsy cases were reported in 1974, much knowledge has been accumulated about the clinicopathological characteristics of ORG. The condition ORG is defined as a proteinuric glomerulopathy with glomerulomegaly in obese patients, in the absence of clinical and histopathological evidence of other renal diseases.[@bib6], [@bib7], [@bib8], [@bib9], [@bib10] Previous interventional studies examining renal physiological parameters before and after bariatric surgery have shown that obesity is closely associated with increased total kidney glomerular filtration rate (GFR).[@bib11]^,^[@bib12] Histopathologically, glomerulomegaly and focal segmental glomerulosclerosis (FSGS) found in ORG are very likely caused by single-nephron hyperfiltration following abnormally increased renal plasma flow and filtration fraction.[@bib7]^,^[@bib11]^,^[@bib12] However, abnormalities in single-nephron GFR (SNGFR) in ORG have not been demonstrated because of technical difficulties in measuring SNGFR in the clinical setting.

Recent studies have developed a method to estimate total glomerular number per kidney in living kidney donors by the combination of computed tomographic angiography and biopsy-based stereology.[@bib13]^,^[@bib14] By dividing the total nephron GFR by the total number of nonsclerotic (functioning) glomeruli in both kidneys, the method showed that the mean values for SNGFR were stable during age-related loss of functioning nephrons, and identified several plausible factors influencing SNGFR in healthy subjects, such as height of more than 190 cm, obesity, and a family history of end-stage renal disease.[@bib15] Recently, we have further modified the method and established a regression equation model to estimate kidney cortical volume by measuring kidney parenchymal volume using unenhanced CT images in humans.[@bib16] Evaluation of cortical volume by this method allows estimation of total glomerular number per kidney in patients with renal diseases who are often not suitable candidates for image analyses using contrast media. This study applied the combined methods of unenhanced computed tomography (CT) and biopsy-based stereology to estimate total glomerular number and SNGFR in patients with ORG.

Methods {#sec1}
=======

Patients {#sec1.1}
--------

The study cohort included obese adult Japanese patients with native kidney biopsy diagnosis of ORG at Jikei Hospital, Tokyo, and Jikei Kashiwa Hospital, Chiba, from 2008 to 2017. Indications for biopsy were renal impairment (eGFR \<60 ml/min) and/or overt proteinuria (\>0.5 g/d). Patients were recruited according to exclusion criteria as previously described.[@bib17] Briefly, patients with renal dysfunction or urinalysis abnormalities prior to becoming obese and those who exhibited acute-onset nephrotic syndrome, which is an atypical presentation for ORG, were excluded. Patients with impaired glucose tolerance alone, as defined as an HbA1c of 6.5% or greater (National Glycohemoglobin Standardization Program \[NGSP\]) at the time of biopsy diagnosis, were not excluded. However, patients were excluded if they had a history of impaired glucose tolerance for more than 5 years or any extra-renal complications of diabetes. Renal histological features of ORG were defined as glomerulomegaly with or without FSGS lesions.[@bib18] Patients were excluded if they showed typical clinical and histological findings of other primary or secondary kidney diseases including diabetic nephropathy. This study was approved by the ethics review board of Jikei University School of Medicine (30-385 9406) and conducted according to the Declaration of Helsinki.

Definitions {#sec1.2}
-----------

Obesity in Japanese subjects was defined as body mass index (BMI) greater than 25 kg/m^2^.[@bib19] Body surface area (BSA) was determined by the equation as follows: BSA (m^2^) = weight^0.425^ (kg) × height^0.725^ (cm) × 71.84 × 10^--4^.[@bib20] Patients were recruited retrospectively from renal biopsy archives during the study period ([Figure 1](#fig1){ref-type="fig"}). Renal biopsy specimens of kidney transplant donors with or without obesity and showing no evidence of kidney disease were used as control groups. Urinary protein excretion (UPE) was determined as total amount of UPE per day by 24-hour urine collection. The 24-hour creatinine clearance rate (CCr) was calculated using measured serum creatinine concentration and urine creatinine concentration in the urine collection. The estimated GFR (eGFR) was calculated using a modified 3-variable equation for the GFR of Japanese individuals[@bib21]: eGFR = 194 × age^−0.287^ × sCr^−1.094^ (×0.739 if female), where sCr is the serum creatinine level. Values for CCr and eGFR were calculated without adjustment for BSA. Chronic kidney disease (CKD) stages were defined as follows: G1, G2, G3a, G3b, G4, and G5 for eGFR ≥90, 60--89, 45--59, 30--44, 15--29 and \<15 ml/min per 1.73 m^2^, respectively. Hypertension was defined as a systolic blood pressure \>140 mm Hg and/or diastolic blood pressure \>90 mm Hg, or use of antihypertensive drugs. Subjects using antihypertensive medications, such as renin−angiotensin−aldosterone system (RAAS) inhibitors, for the purpose of renoprotection despite a normal blood pressure, were considered to be normotensive. The SNGFR and single-nephron UPE (SNUPE) were calculated by dividing per day values for eGFR and UPE by total number of glomeruli excluding globally sclerotic glomeruli in both kidneys.Figure 1Patient selection. A total of 2216 patients underwent renal biopsy at our facility from 2008 to 2017. Of these patients, 65 were diagnosed with obesity-related glomerulopathy (ORG), and 17 were excluded from this study due to lack of computed tomographic data or inadequate glomerular number or cortical area in biopsy specimens. BMI, body mass index.

Pathological Analysis {#sec1.3}
---------------------

All kidney specimens included in this study were obtained by 18-gauge needle biopsy. Implantation biopsies of 1 hour after recirculation were used for the analyses of kidney transplant donors. Kidney tissues were embedded in paraffin, cut into 3-μm sections, and stained with hematoxylin--eosin, periodic acid−Schiff, Masson's trichrome, and periodic acid--methenamine silver. All biopsy specimens were subjected to immunohistochemical staining with the routine panel of antibodies, including IgG, IgA, IgM, C3, and C1q, and electron microscopy studies. The area of interstitial fibrosis/tubular atrophy was semiquantitatively evaluated and scored as the percentage of total cortex involved, with 1% to 5% rounded to 5%, and other values rounded to the closest 10%. The average values for interstitial fibrosis/tubular atrophy were estimated across the entirety of each biopsy specimen. The percentages of all glomeruli in the biopsy specimen with segmental glomerulosclerosis and with global glomerulosclerosis were calculated. The histologic subtype of FSGS was determined for each glomerulus including tip, collapsing, cellular, perihilar, and not otherwise specified (NOS) lesions.[@bib18]

Morphological Measurements {#sec1.4}
--------------------------

Computed tomographic images of kidneys were acquired using the Aquilion Prime (Toshiba Medical Systems, Otawara, Japan), the Definition AS+ (Siemens, Munich, Germany) or the Definition flash (Siemens). The thickness of the obtained image was in the range of 3.0 to 5.0 mm. The parenchymal volume of kidneys was measured by the unenhanced CT images as previously described using software (ITK-SNAP version 1.1; University of Pennsylvania, Philadelphia, PA; [www.itksnap.org](http://www.itksnap.org){#intref0010}).[@bib14] The cortical volume of kidneys was created by the estimation equation models as follows: estimated cortical volume (cm^3^) = −1.3 (intercept) + 0.71 × parenchymal volume (cm^3^).[@bib22]

The nonsclerotic nephron number was estimated as the number of non−globally sclerotic glomeruli, including glomeruli with segmentally sclerotic lesions, according to the method established by Denic *et al.*[@bib13] The number of nonsclerotic glomeruli per kidney was calculated by multiplying the total cortical volume (mm^3^) by the numerical density of nonsclerotic glomeruli (number per cubic millimeter \[mm^3^\] of cortex). These values were divided by 2 (per kidney), by 1.43 to correct for tissue volume shrinkage due to paraffin embedding, and by 1.268 to correct for volume shrinkage due to loss of tissue perfusion pressure.[@bib23]^,^[@bib24]

Computerized image analyzer (Aperio Image Scope 12.4, Leica Microsystems, Wetzlar, Germany) was used to measure the areas of all glomerular capillary tufts and the area of obtained renal cortex. The area of the outer capillary loops including podocytes was defined as glomerular tuft area. ([Supplementary Figure S1A](#appsec1){ref-type="sec"}). Glomeruli with global glomerulosclerosis were excluded from the measurements of tuft area, whereas glomeruli with segmental glomerulosclerosis were included ([Supplementary Figure S1B](#appsec1){ref-type="sec"}). Mean glomerular capillary area (GA) was calculated by averaging all the measured areas of glomerular capillary loops.[@bib22]^,^[@bib25] The mean glomerular volume (GV) was calculated from the measured GA: GV = (GA)^3/2^ × β/*d*, where β is a dimensionless shape coefficient (β = 1.38 for spheres) and *d* is a size distribution coefficient (*d* = 1.01) used to adjust for variation in glomerular size.[@bib23]^,^[@bib26] The nonsclerotic glomerular density (per cubic millimeter of cortex) was calculated using the stereological method of Weibel−Gomez as follows[@bib26]:NSG density = $\frac{1}{\beta}\ \  \times \ \ \sqrt[2]{\frac{\left( \frac{Total\ number\ of\ NSG}{Area\ of\ cortex} \right)^{3}}{\frac{Total\ area\ of\ NSG}{Area\ of\ cortex}}}$ , where β is a dimensionless shape coefficient (β = 1.382 for spheres). The sclerotic glomerular density (per cubic millimeter of cortex) was identically calculated: sclerotic glomerular density = $\frac{1}{\beta}\ \  \times \ \ \sqrt[2]{\frac{\left( \frac{Total\ number\ of\ sclerotic\ glomeruli}{Area\ of\ cortex} \right)^{3}}{\frac{Total\ area\ of\ sclerotic\ glomeruli}{Area\ of\ cortex}}}$. The total number of nephrons was estimated based on glomerular density (per cubic millimeter of cortex) as the sum of non−globally sclerotic glomerular density and globally sclerotic glomerular density.

Statistical Analysis {#sec1.5}
--------------------

Continuous variables were expressed as mean ± SD. Continuous variables were compared by the Mann--Whitney *U* test to compare variables between 2 groups. Categorical variables were expressed as percentages and compared by the χ^2^ test. The Kruskal--Wallis test and the Jonckheere--Terpstra test were used to compare variables among 3 or more groups, as appropriate. The Dunn--Bonferroni test was used as a post hoc analysis. Values of *P* \< 0.05 were considered statistically significant. All statistical analyses were performed using the SPSS software package version 25.0 (IBM Corp., Armonk, NY).

Results {#sec2}
=======

Clinical Characteristics at the Time of Biopsy Diagnosis {#sec2.1}
--------------------------------------------------------

The clinicopathological characteristics of the patients at the time of renal biopsy are shown in [Table 1](#tbl1){ref-type="table"}. All ORG patients included in this cohort were Japanese, with mean age of 48.6 ± 11.5 years, and 61% were male. Of the 48 ORG patients, 37 (77%) were diagnosed as hypertensive at the time of biopsy. By histopathological analysis, 20 ORG patients (42%) had FSGS lesions, and 31 of 931 glomeruli from 48 patients showed FSGS lesions, 13 (42%) of which were perihilar and 18 (58%) of which were NOS lesions. No cellular, collapsing, or tip lesions of FSGS were identified in this cohort. The values for mean glomerular volume that included the glomeruli with segmental sclerosis in the calculation were not significantly different from those that excluded the glomeruli with segmental sclerosis (*P* = 0.204). Among these 48 Japanese ORG patients, nonsclerotic nephron number ranged from 149,000 to 1,055,000 per kidney. The mean nonsclerotic glomerular number and mean glomerular number including globally sclerotic glomeruli in ORG patients were 456,000 ± 235,000 and 676,000 ± 272,000 per kidney, respectively.Table 1Clinical characteristics at the time of biopsy diagnosis in ORG patientsVariableAll patients (n = 48)Clinical findings Age, yr48.6 ± 11.5 Sex, male, % (n)60.4 (29) BMI, kg/m^2^29.5 ± 3.4 BSA, m^2^1.88 ± 0.19 Hypertension, % (n)77.1 (37) Serum creatinine, mg/dl1.16 ± 0.70 eGFR, ml/min68 ± 32 24-h CCr, ml/min102 ± 50 UPE, mg/d1347 ± 1498 Serum albumin, g/dl4.0 ± 0.4 Serum uric acid, mg/dl7.0 ± 1.4 Triglycerides, mg/dl280 ± 253 RAAS inhibitors, % (n)62.5 (30)Histopathological findings Total number of glomeruli per biopsy specimen19.1 ± 10.4 Number of nonsclerotic glomeruli per biopsy specimen14.6 ± 9.7 Glomeruli affected by global glomerulosclerosis, %23.8 ± 19.4 Patients with segmental glomerulosclerosis, % (n)41.7 (20) Glomeruli affected by segmental glomerulosclerosis, %4.0 ± 7.2 FSGS variant, % Glomeruli with perihilar lesion1.7 ± 4.0 Glomeruli with NOS lesion2.3 ± 5.7 Glomeruli with cellular lesion0 Glomeruli with collapsing lesion0 Glomeruli with tip lesion0 Interstitial fibrosis/ tubular atrophy, %17.1 ± 19.9 Arteriosclerotic lesions, %, grade 0/1/2[a](#tbl1fna){ref-type="table-fn"}28/40/32 Arteriolar hyalinosis, %, grade 0/1/2[b](#tbl1fnb){ref-type="table-fn"}25/46/29Renal morphological parameters Renal parenchymal volume, cm^3^/kidney154 ± 44 Renal cortical volume, cm^3^/kidney110 ± 32 Mean glomerular volume, ×10^6^ μm^3^ Including glomeruli with segmental glomerulosclerosis5.01 ± 2.47 Excluding glomeruli with segmental glomerulosclerosis5.05 ± 2.50 Mean areal glomerular density, /mm^2^1.54 ± 0.65 Mean volumetric glomerular density, /mm^3^7.73 ± 3.81 Total nonsclerotic glomerular number, ×10^6^/kidney0.456 ± 0.235 Total globally sclerotic glomerular number, ×10^6^/kidney0.220 ± 0.198 Single-nephron eGFR, nl/min85 ± 42 Single-nephron UPE, μg/day2.36 ± 3.60[^1][^2][^3]

Comparison of Clinicopathological Findings Between ORG Patients With Preserved Renal Function and Kidney Transplant Donors With or Without Obesity {#sec2.2}
--------------------------------------------------------------------------------------------------------------------------------------------------

Clinicopathological characteristics were evaluated in the ORG subgroups with preserved renal function of CKD stage 1 or 2 and compared with kidney transplantation donors as healthy controls ([Table 2](#tbl2){ref-type="table"}). The measured parenchymal volume and the estimated cortical volume of the kidneys were significantly higher in patients with ORG than in obese and nonobese controls. By contrast, mean areal and volumetric glomerular densities were significantly lower in the ORG patients than in obese and nonobese controls. The degrees of global and segmental glomerulosclerosis were higher in ORG patients with preserved renal function than in obese and nonobese donor controls. The nonsclerotic glomerular number was not statistically different among these 3 study groups. In comparison with those of obese and nonobese donor controls, the globally sclerotic glomerular number was significantly larger in ORG patients with preserved renal function. Total and single-nephron parameters were evaluated among the ORG patients with preserved renal function and compared with living kidney donors ([Figure 2](#fig2){ref-type="fig"}). The ORG patients with CKD stage 1 or 2 had significantly higher mean GV than the obese and nonobese donor controls. The ORG patients with CKD stage 1 or 2 had higher eGFR and SNGFR than the nonobese donor controls and showed a trend toward higher eGFR and SNGFR than the obese donor controls.Table 2Comparison of clinicopathological findings between ORG patients with a preserved renal function and kidney transplant donorsVariableNonobese donors (n = 20)Obese donors (n = 13)ORG\
CKD stage 1, 2 (n = 25)*P* value[a](#tbl2fna){ref-type="table-fn"}Clinical findings Age, yr52.8 ± 6.452.1 ± 8.345.0 ± 10.7[b](#tbl2fnb){ref-type="table-fn"}0.010 Sex, male % (n)40.0 (8)38.5 (5)64.0 (16)0.178 BMI, kg/m^2^21.4 ± 1.927.0 ± 1.8[b](#tbl2fnb){ref-type="table-fn"}29.4 ± 3.2[b](#tbl2fnb){ref-type="table-fn"}\<0.001 BSA, m^2^1.58 ± 0.151.74 ± 0.131.90 ± 0.22[b](#tbl2fnb){ref-type="table-fn"}\<0.001 Hypertension, % (n)5.0 (1)15.4 (2)68.0 (17)\<0.001 Serum creatinine, mg/dl0.71 ± 0.130.71 ± 0.090.77 ± 0.170.347 eGFR, ml/min70 ± 1179 ± 1391 ± 26[b](#tbl2fnb){ref-type="table-fn"}0.003 24-h CCr, ml/min108 ± 27109 ± 23136 ± 39[b](#tbl2fnb){ref-type="table-fn"}0.016 Urinary protein excretion, mg/d25 ± 2229 ± 41874 ± 770[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}\<0.001 Serum albumin, g/dl4.1 ± 0.34.4 ± 0.3[b](#tbl2fnb){ref-type="table-fn"}4.2 ± 0.40.015 Serum uric acid, mg/dl4.6 ± 0.95.2 ± 0.76.5 ± 1.5[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}\<0.001 Triglyceride, mg/dl206 ± 24144 ± 51[b](#tbl2fnb){ref-type="table-fn"}291 ± 2840.023 RAAS inhibitors, % (n)0 (0)7.7 (1)60.0 (15)0.002Histopathological findings Total number of glomeruli per biopsy6.8 ± 2.48.2 ± 3.519.1 ± 10.7[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}\<0.001 Number of nonsclerotic glomeruli per biopsy6.6 ± 2.38.0 ± 3.116.3 ± 9.9[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}\<0.001 Total cortical area, mm^2^2.7 ± 0.83.3 ± 0.79.5 ± 4.7\<0.001 Global glomerulosclerosis, %3.3 ± 6.31.6 ± 4.315.6 ± 14.9[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}\<0.001 Segmental glomerulosclerosis, %001.8 ± 3.6[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}0.006 Interstitial fibrosis/ tubular atrophy, %4.8 ± 4.86.1 ± 4.87.4 ± 6.80.459Renal morphological parameters Renal parenchymal volume, cm^3^/kidney119 ± 23138 ± 22173 ± 48[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}\<0.001 Renal cortical volume, cm^3^/kidney85 ± 1798 ± 17123 ± 34[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}\<0.001 Mean areal glomerular density, /mm^2^2.50 ± 0.872.34 ± 0.591.71 ± 0.63[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}0.002 Mean volumetric glomerular density, /mm^3^14.6 ± 5.412.4 ± 3.58.42 ± 3.89[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}\<0.001 Total nonsclerotic glomerular number, ×10^6^/kidney0.652 ± 0.2110.673 ± 0.2170.542 ± 0.2270.103 Total globally sclerotic glomerular number, ×10^6^/kidney0.034 ± 0.0660.031 ± 0.0790.161 ± 0.168[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}\<0.001 Single-nephron eGFR, nl/min59 ± 2164 ± 2197 ± 43[b](#tbl2fnb){ref-type="table-fn"}0.001[^4][^5][^6][^7]Figure 2Single-nephron parameters in obesity-related glomerulopathy (ORG) patients with preserved renal function. Total and single-nephron parameters, including (a) mean glomerular volume (GV), (b) estimated glomerular filtration rate (eGFR), and (c) single-nephron glomerular filtration rate (SNGFR) were evaluated among the ORG patients with preserved renal function of chronic kidney disease (CKD) stage G 1, 2 and compared with kidney transplantation donors with or without obesity. Values represent the mean ± SD of evaluations from each group. Differences among groups were analyzed by the Kruskal−Wallis test with the Dunn−Bonferroni test. GFR, glomerular filtration rate.

Comparison of Clinicopathological Findings in ORG Patients With Different Renal Function Stages {#sec2.3}
-----------------------------------------------------------------------------------------------

Clinicopathological characteristics were compared among the ORG subgroups defined by CKD stage ([Table 3](#tbl3){ref-type="table"}). Estimated cortical volume of the kidneys and mean volumetric glomerular density tended to decrease in accordance with the progression of renal function stages, with no statistically significant differences among the ORG subgroups. Mean areal glomerular density showed a statistically significant tendency to decrease in accordance with the progression of CKD stages. Total and single-nephron parameters were compared among the ORG subgroups categorized by CKD stage ([Figure 3](#fig3){ref-type="fig"}). The total nonsclerotic glomerular number decreased as renal function declined. Mean GV did not show statistically significant differences among the ORG subgroups with different stages of CKD. Both eGFR and SNGFR decreased in accordance with the advancement of CKD stages. Values for UPE increased and the values for SNUPE were further increased with the advancement of CKD stages. Similar results for single-nephron parameters were confirmed in the subgroups treated with antihypertensive medications including RAAS inhibitors at the time of biopsy diagnosis ([Supplementary Figure S2](#appsec1){ref-type="sec"}).Table 3Comparison of clinicopathological findings in ORG patients with different renal function stagesVariableORG\
CKD stage 1 (n = 8)ORG\
CKD stage 2 (n = 17)ORG\
CKD stage 3a (n = 10)ORG\
CKD stage 3b (n = 7)ORG\
CKD stage 4, 5 (n = 6)*P* value for trend[a](#tbl3fna){ref-type="table-fn"}Clinical findings Age, yr41.1 ± 15.246.9 ± 7.749.2 ± 8.655.9 ± 10.650.7 ± 14.80.019 Sex, male % (n)50.0 (4)70.6 (12)60.0 (6)71.4 (5)50.0 (3)0.974 BMI, kg/m^2^30.3 ± 3.729.1 ± 3.030.6 ± 4.328.6 ± 3.529.1 ± 2.70.665 BSA, m^2^1.89 ± 0.241.91 ± 0.221.85 ± 0.161.90 ± 0.201.83 ± 0.130.479 Hypertension, % (n)50.0 (4)76.5 (13)70.0 (7)71.4 (5)100 (6)0.046 Serum creatinine, mg/dl0.59 ± 0.080.86 ± 0.14[b](#tbl3fnb){ref-type="table-fn"}1.09 ± 0.15[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}1.42 ± 0.18[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}^,^[d](#tbl3fnd){ref-type="table-fn"}2.67 ± 0.92[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}^,^[d](#tbl3fnd){ref-type="table-fn"}^,^[e](#tbl3fne){ref-type="table-fn"}\<0.001 eGFR, ml/min per 1.73 m^2^106 ± 1471 ± 8[b](#tbl3fnb){ref-type="table-fn"}54 ± 3[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}39 ± 5[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}^,^[d](#tbl3fnd){ref-type="table-fn"}20 ± 5[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}^,^[d](#tbl3fnd){ref-type="table-fn"}^,^[e](#tbl3fne){ref-type="table-fn"}\<0.001 24-h CCr, ml/min145 ± 42132 ± 3983 ± 18[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}61 ± 19[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}33 ± 15[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}^,^[d](#tbl3fnd){ref-type="table-fn"}\<0.001 Urinary protein excretion, mg/d780 ± 879918 ± 737940 ± 7432703 ± 25572555 ± 19860.005 Serum albumin, g/dl4.1 ± 0.14.2 ± 0.44.1 ± 0.43.7 ± 0.53.7 ± 0.40.003 Serum uric acid, mg/dl6.6 ± 2.26.5 ± 1.17.2 ± 1.37.0 ± 0.98.3 ± 0.8[c](#tbl3fnc){ref-type="table-fn"}0.014 Triglyceride, mg/dl362 ± 459258 ± 158254 ± 109365 ± 344172 ± 1130.761 RAAS inhibitors, % (n)25.0 (2)70.6 (12)60.0 (6)57.1 (4)83.3 (5)0.281Histopathological findings Total number of glomeruli per biopsy specimen22.3 ± 14.017.6 ± 8.919.0 ± 11.919.9 ± 10.718.3 ± 8.50.825 Number of non-sclerotic glomeruli per biopsy specimen20.3 ± 13.114.4 ± 7.814.4 ± 11.512.7 ± 9.810.1 ± 4.40.075 Global glomerulosclerosis, %10.0 ± 9.318.2 ± 16.525.0 ± 19.634.9 ± 23.643.3 ± 12.0[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}\<0.001 Segmental glomeruloscrelosis, %3.0 ± 3.71.2 ± 3.51.7 ± 2.78.5 ± 8.2[c](#tbl3fnc){ref-type="table-fn"}11.8 ± 13.7[c](#tbl3fnc){ref-type="table-fn"}0.014 Interstitial fibrosis/ tubular atrophy, %5.0 ± 2.78.5 ± 7.912.5 ± 19.228.6 ± 16.5[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}51.7 ± 19.7[b](#tbl3fnb){ref-type="table-fn"}^,^[c](#tbl3fnc){ref-type="table-fn"}^,^[d](#tbl3fnd){ref-type="table-fn"}\<0.001Renal morphological parameters Renal parenchymal volume, cm^3^/kidney184 ± 65168 ± 40140 ± 20135 ± 31122 ± 390.003 Renal cortical volume, cm^3^/kidney131 ± 46119 ± 28100 ± 1496 ± 2287 ± 280.057 Mean areal glomerular density, /mm^2^2.06 ± 0.821.54 ± 0.451.51 ± 0.701.31 ± 0.721.17 ± 0.360.005 Mean volumetric glomerular density, /mm^3^10.70 ± 5.357.34 ± 2.517.37 ± 4.117.02 ± 4.256.27 ± 2.480.050 Total nonsclerotic glomerular number, ×10^6^/kidney0.686 ± 0.2600.475 ± 0.1810.391 ± 0.2010.365 ± 0.2460.315 ± 0.208[c](#tbl3fnc){ref-type="table-fn"}\<0.001 Total globally sclerotic glomerular number, ×10^6^/kidney0.103 ± 0.0800.188 ± 0.1850.229 ± 0.1910.289 ± 0.2130.368 ± 0.2000.007[^8][^9][^10][^11][^12][^13]Figure 3Comparison of single-nephron parameters in obesity-related glomerulopathy (ORG) patients with different renal function stages. Total and single-nephron parameters, including (a) otal nonsclerotic glomerular number, (b) mean glomerular volume (GV), (c) estimated glomerular filtration rate (eGFR), (d) single-nephron glomerular filtration rate (SNGFR), (e) urinary protein excretion (UPE), and (f) single-nephron urinary protein excretion (SNUPE) were compared among the ORG subgroups categorized based on different renal function stages of chronic kidney disease (CKD) G1, G2, G3a, G3b, and G4, 5. Values represent the mean ± SD of evaluations from each group. Differences among groups were analyzed by the Jonckheere−Terpstra test with the Dunn−Bonferroni test. GFR, glomerular filtration rate. ^a^*P* \< 0.05 versus CKD stage 1. ^b^*P* \< 0.05 versus CKD stage 2. ^c^*P* \< 0.05 versus CKD stage 3a. ^d^*P* \< 0.05 versus CKD stage 3b.

Discussion {#sec3}
==========

Using unenhanced CT and biopsy-based stereology, we demonstrate for the first time in humans the development of elevated SNGFR levels in ORG patients compared to those in healthy subjects. Importantly, an increase in SNGFR was not observed in transplant donors with comparable levels of obesity, suggesting that obesity alone is not sufficient to induce these changes in all obese subjects. These results are consistent with the typical histopathological features of marked glomerulomegaly and maladaptive FSGS lesions, indicating abnormal intraglomerular hemodynamics in ORG patients.[@bib6]^,^[@bib27]^,^[@bib28] Our results further show that SNGFR is decreased in accordance with the progression of CKD stages, with no difference in the mean GV between the subgroups. This may be caused in part by a tendency toward more afferent arteriolar hyalinosis with advancing CKD.[@bib29] Mesangial cell contraction caused by RAAS activation leading to a decreased capillary surface area also could contribute to decreased SNGFR without reducing mean GV.[@bib30] Of note, SNUPE was much higher in the ORG subgroups with more advanced CKD stages. These results suggest that the initial glomerular hyperfiltration with compensatory glomerular enlargement is an early response that is followed by vulnerability of the glomerular filtration barrier to injury, representing a process of decompensated hyperfiltration at the single-nephron level during ORG progression. Experimental studies in obese rats suggest that glomerular hypertrophy exerts mechanical strain on maximally hypertrophied podocytes, leading to podocyte failure and depletion, which in turn could mediate increasing proteinuria.[@bib31]

Although the origin of glomerulomegaly in patients with ORG is incompletely understood, several plausible mechanisms have been proposed.[@bib28] These include glomerular adaptive changes due to a mismatch between body size and nephron mass and an increase in the glomerular capillary number. Our previous studies identified low areal glomerular density as a typical renal histopathological finding in ORG biopsy specimens.[@bib17]^,^[@bib32] In our current study cohort, we again confirmed that mean areal glomerular density in ORG patients was significantly lower than in obese or nonobese control subjects. Based on this simple metric, we had assumed that the nephron endowment in ORG patients was low.[@bib28]^,^[@bib32], [@bib33], [@bib34] Unexpectedly, our current results fail to support this hypothesis. As a whole, ORG patients did not show an apparently low total glomerular number per kidney as compared to donor control subjects when globally sclerotic glomeruli were included in the calculation.

An overriding question in the pathogenesis of ORG is why only a small subset of obese individuals develop ORG. Our current results show that ORG closely associates with a decrease in nonsclerotic glomerular number. Thus, our results support the possibility that a low number of functioning nephrons, either inherent or acquired, is one of the risk factors sensitizing obese individuals to ORG progression. However, the similar numbers of nephrons (with or without globally sclerotic glomeruli) in ORG patients with preserved renal function and in healthy donor controls suggest that low nephron number is not likely to be the sole predisposing factor to induce ORG in combination with obesity. Similar to variability in nephron number, recent studies have revealed broad variability in podocyte number per glomerulus among normal individuals.[@bib35]^,^[@bib36] Mismatch between abnormally enlarged glomeruli and individual podocyte endowment could constitute another predisposing mechanism to glomerular injury in ORG patients.[@bib37] Finally, our findings of low areal glomerular density together with enlarged parenchymal volume and cortical volume support tubular hypertrophy occurring as part of a co-ordinated hypertrophic nephron response in ORG.

A recent study reported that CCr overestimates measured GFR due to tubular secretion of creatinine.[@bib38] In fact, CCr was approximately 30% higher than eGFR in this study cohort. This study therefore used eGFR-based SNGFR as a substitute for measured GFR-based SNGFR. In our donor controls, the eGFR-based SNGFR was 20% lower and CCr-based SNGFR was 10% higher as compared to the SNGFR value (80 ± 40 nl/min) estimated by an iothalamate-based measurement of the GFR in the US donor cohort.[@bib15] Given the potential racial differences in nephron numbers and SNGFR, validation studies using measured GFR are needed among different races.

This study has several important limitations. First, the small number of patients recruited in this study may have influenced the statistical power. Second, our study's cross-sectional design does not prove causal relationships between glomerular number and renal outcomes. Third, a large proportion of our patients were receiving treatment with antihypertensive medications including RAAS inhibitors, which could modify the SNGFR and SNUPE. Fourth, information on birth weight, a surrogate for nephron number at birth, was unavailable in this study. Finally, the small glomerular sampling by needle biopsy may have significantly influenced the results, as the distribution of individual glomerular adaptive responses is not uniform across the kidney. Furthermore, the glomeruli and cortical area obtained in the biopsy specimen of donors were substantially smaller than those of ORG patients. These discrepancies in the number of glomeruli and/or cortical area may have affected the measurement of glomerular density and total glomerular number.

In conclusion, our results provide morphometric and functional correlates for single-nephron parameters in ORG patients. Our data suggest, for the first time, that single-nephron glomerular hyperfiltration indeed occurs in human kidneys with ORG and is a feature of early-stage ORG with preserved renal function. Despite persistent elevations in mean GV during ORG progression, SNGFR tended to decline with more advanced stages of CKD, in parallel with worsening proteinuria. Together, our findings suggest that impairment in individual glomerular barrier function, as a result of decompensated hyperfiltration responses, underlie ORG progression.
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**Figure S1.** Measurement of glomeruli. Representative light microscopic measurement for non-sclerotic glomeruli (A) and glomeruli with FSGS lesions (B) (PAS, ×200).

**Figure S2.** Comparison of single-nephron parameters in ORG patients treated with RAAS inhibitors at the time of biopsy diagnosis. Total and single-nephron parameters, including total nonsclerotic glomerular number (A), mean glomerular volume (GV) (B), estimated GFR (eGFR) (C), single-nephron GFR (SNGFR) (D), urinary protein excretion (UPE) (E), and single-nephron urinary protein excretion (SNUPE) (F) were compared among the ORG subgroups categorized based on different renal function stages of CKD G1, G2, G3a, G3b, and G4, 5 (n = 4, 11, 6, 4, and 5, respectively.). Values represent the mean ± SD of evaluations from each group. Differences among groups were analyzed by the Jonckheere−Terpstra test with the Dunn−Bonferroni test. ^a^*P* \< 0.05 versus CKD stage 1, ^b^*P* \< 0.05 versus CKD stage 2, ^c^*P* \< 0.05 versus CKD stage 3a, ^d^*P* \< 0.05 versus CKD stage 3b.

[^1]: BMI, body mass index; BSA, body surface area; CCr, creatinine clearance rate; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; NOS, not otherwise specified; ORG, obesity-related glomerulopathy; RAAS, renin−angiotensin−aldosterone system; UPE, urinary protein excretion.

[^2]: Severity of arterial lesions with no intimal thickening was defined as grade 0, those with ≤50% intimal thickening as grade 1, and those with \>50% as grade 2.

[^3]: Grade of arteriolar lesions was semiquantitatively evaluated based on the percentage of arterioles per biopsy specimen exhibiting hyalinosis, as follows: grade 0, \<5% lesions; grade 1, 5% to 25% lesions; and grade 2, \>25% lesions.

[^4]: BMI, body mass index; BSA, body surface area; eGFR, estimated glomerular filtration rate; ORG, obesity-related glomerulopathy; RAAS, renin--angiotensin--aldosterone system.

[^5]: Kruskal--Wallis test with Dunn--Bonferroni test.

[^6]: *P* \< 0.05 vs. nonobese donors.

[^7]: *P* \< 0.05 vs. obese donors.

[^8]: BMI, body mass index; BSA, body surface area; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ORG, obesity-related glomerulopathy; RAAS, renin−angiotensin−aldosterone system.

[^9]: Jonckheere−Terpstra test with Dunn−Bonferroni test.

[^10]: *P* \< 0.05 vs. CKD stage 1.

[^11]: *P* \< 0.05 vs. CKD stage 2.

[^12]: *P* \< 0.05 vs. CKD stage 3a.

[^13]: *P* \< 0.05 vs. CKD stage 3b.
